Renal Cancer Trials

To go back to the main page, click here

S.No	Drug Name	Biological Name	Developer	Current Development Phase	Additional Information	Start Date	Completion Date	Source
11	Sunitinib, Cyclophosphamide	IMA901 plus GM-CSF	Immatics Biotechnologies GmbH	III	The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy with sunitinib. Secondary objectives include a subgroup analysis of overall survival in patients defined by a certain biomarker signature, the investigation of progression-free survival, best tumor response, safety, and immunological parameters	2010	2011	Source
12	-	PSMA/PRAME	MannKind Corporation	I	Completed The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.	2007	2009	Source
13	-	EphA2 Vaccine/ MEDI-543	MedImmune	Preclinical	-	-	-	-
14	-	V934/V935	Merck	I	Completed. This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.	2008	2011	Source
15	-	MGN1601	Mologen AG	I/II	This is a Phase 1/2, proof-of-principle clinical study to assess safety and efficacy of a intradermally administered tumor vaccine (MGN1601). The study will be conducted in patients with advanced renal cell carcinoma.	2010	2019	Source
16	Interferon-alpha	TroVax®	Oxford BioMedica	II	Patients with metastatic renal cell cancer will be enrolled to receive either Trovax® alone or Trovax® plus Interferon Alfa. The study will try to determine whether the use of Trovax® will delay tumor progression.	2006	2008	Source
17	-	AdhTAP	TapImmune	Preclinical	-	-	-	-

To go back to the main page, click here